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Abstract
The production of tumor necrosis factor α (TNF-α) and
interleukin-1β (IL-1β) by monocytes is strongly induced by direct
contact with stimulated T lymphocytes, and this mechanism may
be critical in the pathogenesis of rheumatoid arthritis (RA).
Apolipoprotein A-I (apoA-I) blocks contact-mediated activation
of monocytes, causing inhibition of TNF-α and IL-1β production.
This study examined the hypothesis that apoA-I may have a
regulatory role at sites of macrophage activation by T
lymphocytes in inflamed RA synovial tissue. Synovial tissue
samples were obtained after arthroscopy from patients with
early untreated RA or treated RA and from normal subjects. As
determined by immunohistochemistry, apoA-I was consistently
present in inflamed synovial tissue that contained infiltrating T
cells and macrophages, but it was absent from noninflamed
tissue samples obtained from treated patients and from normal
subjects. ApoA-I staining was abundant in the perivascular
areas and extended in a halo-like pattern to the surrounding
cellular infiltrate. C-reactive protein and serum amyloid A were
not detected in the same perivascular areas of inflamed tissues.
The abundant presence of apoA-I in the perivascular cellular
infiltrates of inflamed RA synovial tissue extends the
observations  in vitro that showed that apoA-I can modify
contact-mediated macrophage production of TNF-α and IL-1β.
ApoA-I was not present in synovium from patients in apparent
remission, suggesting that it has a specific role during phases of
disease activity. These findings support the suggestion that the
biologic properties of apoA-I, about which knowledge is newly
emerging, include anti-inflammatory activities and therefore have
important implications for the treatment of chronic inflammatory
diseases.
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Introduction
Inflammation is a critical host-defense mechanism. One of
its functions is to direct plasma factors and immunoinflam-
matory cells to lesions in order to eradicate infection and
facilitate tissue repair. In many chronic inflammatory dis-
eases, infiltration of the target tissue by blood-derived cells
precedes tissue damage. For example, it is believed that in
rheumatoid arthritis (RA), the initial cellular event in synovial
tissue is proliferation of fibroblast-like synoviocytes, which
release chemokines that contribute to the recruitment of
inflammatory cells, including monocytes and lymphocytes
[1]. It has been proposed that the first cells to infiltrate syn-
ovial tissue are T lymphocytes, suggesting that they have
an important role in pathogenesis. We previously showed
that stimulated T cells induced pathological effects through
direct cellular contact with monocyte–macrophages, caus-
ing the abundant production of interleukin-1β (IL-1β) and
tumor necrosis factor α (TNF-α). This observation has been
confirmed by others (for review see [2]). The unregulated
production of IL-1β and TNF-α in RA has been recognized
for several years, and their role in the pathophysiology has
been confirmed by the demonstration that targeted block-
ade improves patients' clinical status [3,4].
We therefore postulate that contact-mediated cytokine
production is highly relevant to the pathogenesis and the
maintenance of chronic inflammation in diseases such as
RA. Regulating a potent mechanism that induces both IL-
1β and TNF-α may be important in maintaining a low level
of monocyte activation within the bloodstream. We recently
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identified apolipoprotein A-I (apoA-I) as a specific inhibitor
of contact-mediated activation of monocytes [5]. ApoA-I is
a 'negative acute-phase protein' and the principal protein of
high-density lipoproteins (HDLs). Variations of apoA-I con-
centration have been observed in several inflammatory dis-
eases. In RA, the levels of circulating apoA-I and HDL
cholesterol in untreated patients are lower than in normal
controls [6-8]. In contrast, apoA-I levels were increased in
the synovial fluid of patients with RA [9], although these
were still only one-tenth those in plasma. The elevation of
apoA-I levels in the synovial fluid of untreated patients with
RA was accompanied by increased cholesterol levels, sug-
gesting infiltration of HDL particles in the inflamed joint. In
this study, we examined synovial tissue from patients with
active RA in order to determine if apoA-I infiltration had
occurred at sites of contact between T lymphocytes and
macrophages.
Materials and methods
Synovial tissue samples
Synovial biopsies were obtained from the knee joints after
arthroscopy in patients diagnosed with RA, who had all
given their informed consent. Normal synovium was
obtained from a patient without arthritis who was having a
leg amputated. Arthroscopy and biopsy were performed
under local anesthesia using a 2.7-mm Storz arthroscope
and a 1.5-mm grasping forceps. The sampled tissue was
immediately embedded in Tissue-Tek® OCT compound
(Sakura, Zoeterwoude, the Netherlands) and snap frozen in
liquid nitrogen.
Monoclonal antibodies
All antibodies used were murine antihuman monoclonal
antibodies (antibodies were diluted in PBS; anti-apoA-I
contained 0.6 M sodium chloride); anti-apoA-I, type 2 (Cal-
biochem-Novabiochem Corporation, Darmstadt, Ger-
many), was used at 1/3000 dilution; anti-C-reactive protein
(CRP), clone CRP-8 (Sigma Chemicals, St Louis, MO,
USA), at 1/200 dilution; anti-Von Willebrand factor/factor
VIII-related antigen (FVIII), clone F8/86 (DAKO, Glostrup,
Denmark), at 1/50 dilution; and anti-acute-phase serum
amyloid A (A-SAA) (gift from Dr AS Whitehead, Philadel-
phia, PA, USA), at 1/1200. Isotype-matched murine IgG1
(DAKO) was used at the same concentration as each of the
primary antibodies.
Immunohistochemistry
Synovial tissue sections were cut at 7 µm and mounted on
slides coated with 3-aminopropyltriethoxy-silane (Sigma).
Slides were air-dried overnight, wrapped in foil, and stored
at -80°C. A standard three-stage immunoperoxidase tech-
nique was used, with a Peroxidase VECTASTAIN® Elite
ABC kit (Vector Laboratories, Burlingame, CA, USA).
Slides were removed from the -80°C freezer and allowed to
thaw at room temperature for 20 minutes. Sections were
fixed in acetone for 10 minutes and with normal horse
serum (VECTASTAIN® Elite ABC kit) for 15 minutes. The
relevant primary antibody was added to sections for 1 hour
at room temperature. Sections were washed and incubated
with PBS for 5 minutes. Anti-mouse IgG secondary anti-
body (VECTASTAIN® Elite ABC kit) was added for 30 min-
utes and the ABC solution (VECTASTAIN® Elite ABC kit)
was added to sections for 30 minutes. Sections were
treated with 3% hydrogen peroxide for 7 minutes, washed
in distilled water for 1 minute, and incubated in PBS for 5
minutes, followed by the addition of 3,3'-diaminobenzidine
(Sigma) for 12 minutes. The chromogenic reaction was
stopped by immersion in water. Sections were counter-
stained in Mayer's hemalum, dehydrated in alcohol, cleared
in xylene, and mounted in DPX (BDH, Poole, UK).
Results
The demographic and clinical details of the patients stud-
ied are outlined in Table 1. Synovial tissue samples from
eight patients with active RA were selected. The mean
duration of disease was 19 (range 1–48) months, he mean
swollen joint count was 20 (range 10–36), and the mean
CRP level was 12.3 (range <3 to 22)mg/L. Six patients
were receiving nonsteroidal anti-inflammatory drugs at the
time of synovial biopsy. Two were receiving a disease-mod-
ifying anti-rheumatic drug, methotrexate, 15 mg/week in
both cases. Two were receiving prednisolone, 10 mg/day.
None had received an intra-articular corticosteroid injection
to the biopsied knee joint. Synovial tissue was also
obtained from two patients with quiescent RA (no swollen
joints, CRP <3 mg/L) and from one patient who was unaf-
fected by arthritis. Both patients with quiescent RA were
receiving methotrexate, 7.5 mg/week.
All synovial tissue sections from the eight patients with
active RA showed prominent blood vessels and perivascu-
lar cellular infiltration. Specific apoA-I staining was present
in all samples. The immunohistologic appearances were
consistent, and included prominent endothelial apoA-I
staining of most blood vessels (Fig. 1a). The vessels were
surrounded by a confined area of intense staining that was
consistent with extravasation of apoA-I within the perivas-
cular cell infiltrate. No staining was observed in the nega-
tive control tissue sections (Fig. 1b). In tissue samples
obtained from patients with RA that were in apparent remis-
sion, only faint vascular and perivascular apoA-I staining
was present (Fig. 1e), even though the sections contained
blood vessels that were easily identified (Fig. 1f). As
expected, the cellular infiltrate in these sections was less
intense. There was no perivascular apoA-I staining in the
synovial tissue sample obtained from the knee joint unaf-
fected by arthritis (Fig. 1c). Contrary to the abundant pres-
ence of perivascular apoA-I staining in tissue sections
obtained from patients with active RA, there was no evi-
dence of perivascular CRP or A-SAA. Tissue samples fromAvailable online http://arthritis-research.com/content/6/6/R563
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three patients were studied for the presence of perivascu-
lar CRP. The serum CRP levels were elevated in all three at
the time of biopsy (11–20 mg/L). Faint CRP staining of
endothelial cells was observed (Fig. 1g). Tissue samples
from five patients were studied for the presence of perivas-
cular A-SAA. As expected, A-SAA staining was demon-
strated in lining layer cells but not within the perivascular
infiltrate (Fig. 1h).
Discussion
The most salient observation from this study was apoA-I
infiltration in inflamed synovial tissue and its retention in
perivascular regions, where T lymphocytes and macro-
phages accumulate. The localization of positive acute-
phase proteins, such as CRP and A-SAA, was different
from that of apoA-I: only faint staining, limited to vascular
endothelium, was observed for CRP, and A-SAA was
observed in lining layer cells, which are a known source of
local synthesis [10].
We have previously shown apoA-I to inhibit the production
of both IL-1β and TNF-α in monocytes activated by direct
contact with stimulated T cells. This mechanism may have
a role in regulating monocyte activation in the bloodstream
[5]. This study demonstrated that apoA-I infiltrated perivas-
cular regions of the synovium where A-SAA, which can dis-
sociate apoA-I from HDLs [11], and CRP were absent. The
perivascular localization of apoA-I suggests that it could
have an inhibitory role in zones where T lymphocytes are in
close contact with monocyte–macrophages, with a ten-
dency to form 'lymphoid microstructures' [12]. The
absence of A-SAA suggests that it is unlikely to restrict the
inhibitory activity of apoA-I in the contact-mediated induc-
tion of IL-1β and TNF-α production in tissue [13]. To over-
come apoA-I inhibition, A-SAA would be expected to
localize in the same area. Since apoA-I is virtually absent
from the synovial tissue of patients with inactive RA (Fig.
1c), its presence in actively inflamed tissue suggests that
its infiltration during a flare-up may represent a physiologic
mechanism that inhibits proinflammatory cytokine produc-
tion and limits disease recurrence. The transient infiltration
of apoA-I may also explain why RA, like many other chronic
inflammatory diseases, characteristically presents as a
relapsing–remitting disease in many patients. During
phases of RA associated with joint damage, the inhibitory
Table 1
Demographic and clinical details of patients with active rheumatoid arthritis
Total no. of patients 8
Mean duration of disease (range) 19 (1–48) months
Mean no. of swollen joints (range) 20 (10–36)
Mean C-reactive protein (range) 12.3 (0–22)mg/dL
No. of patients receiving:
NSAIDs 6
DMARDs (MTX 15 mg/wk) 2
Prednisolone 2
DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; NSAID, nonsteroidal anti-inflammatory drug.
Figure 1
Apolipoprotein A-I (apoA-I) is localized in the perivascular region of the  inflamed synovium Apolipoprotein A-I (apoA-I) is localized in the perivascular region of the 
inflamed synovium. (a) Active rheumatoid arthritis (RA) synovium 
stained with anti-apoA-I; (b) active RA synovium stained with isotype-
matched negative control; (c) normal synovium stained with anti-apoA-I; 
(d) normal synovium stained with anti-factor VIII; (e) remission RA syn-
ovium stained with anti-apoA-I; (f) remission RA synovium stained with 
anti-factor VIII; (g) active RA synovium stained with anti-C-reactive pro-
tein; (h) active RA synovium stained with antibody against serum amy-
loid A.Arthritis Research & Therapy    Vol 6 No 6    Bresnihan et al.
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effects of apoA-I on the destructive mechanisms may not
be sufficiently potent.
In RA, variations of apoA-I concentrations were observed in
plasma, where it was decreased, and in synovial fluid,
where it was increased [6-9]. The elevation of apoA-I levels
in synovial fluid of RA patients correlated with a rise in cho-
lesterol, suggesting infiltration of HDL particles into the
inflamed joint. Similarly, active juvenile RA was associated
with reduced HDL blood levels and a significant decrease
in apoA-I concentration in plasma [14]. These studies sug-
gest that variations of apoA-I levels may inversely correlate
with disease activity. The observation that apoA-I can infil-
trate and be retained at the inflammatory site suggests that
apoA-I may inhibit the local triggering of IL-1β and TNF-α
release by monocyte–macrophages that are in direct con-
tact with stimulated T cells in these areas [15].
Conclusion
In conclusion, the localization of apoA-I in inflamed syn-
ovium suggests that it can locally inhibit the production of
proinflammatory cytokines by monocyte–macrophages
upon direct contact with stimulated T cells. Thus, it is pos-
sible that after immune cell infiltration, formation of lym-
phoid-like microstructures, and the proliferation of blood
vessels that resemble high-endothelial venules, inhibitory
plasma components may infiltrate the developing inflamma-
tory lesion. ApoA-I that binds surface factors on stimulated
T cells is retained in the perivascular regions, where it may
limit contact-mediated cytokine induction in monocyte–
macrophages [5] and inhibit critical pathways associated
with disease exacerbation. The alterations in apoA-I infiltra-
tion may also explain fluctuations of disease activity. The
finding that apoA-I can infiltrate inflamed tissue, together
with its newly emerging anti-inflammatory properties, may
have important implications for treatment in chronic inflam-
matory diseases.
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